FRANKFURT (Reuters) - German drugmakers including Stada, Torrent's Heumann and Dr. Reddy's betapharm have appealed a regulator's decision to suspend approval of some drugs over concerns about clinical trials conducted by an Indian company.
Regulators in France, Germany, Belgium and Luxembourg this month suspended marketing approval for 25 drugs over the quality of trial data from India's GVK Biosciences.
Companies that have filed an appeal will be allowed to resume sales of affected products until their appeals are either approved or struck down, Germany's Federal Institute for Drugs and Medical Devices (BfArM) said on Monday.
"We are reviewing the appeals thoroughly and quickly," a spokesman for BfArM said.
The regulator last week had published a list of 80 affected products that their manufacturers would not be allowed to sell until they had provided new clinical data.
(Reporting by Frank Siebelt; writing by Maria Sheahan; editing by Jason Neely)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
